All In MedTech

FDA Clearance Tracker · P010032-S237

Eterna SCS and Proclaim SCS Systems

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 13, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jan 13, 2026

Approved

Time to decision

249 days

Received May 9, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P010032-S237
Device name
Eterna SCS and Proclaim SCS Systems
Applicant location
Plano, TX
Received
May 9, 2025
Decided
Jan 13, 2026
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P010032

Device type

Device class
Class III

Every decision under product code LGW

FDA's approval statement

As written in FDA's record.

approval for labeling changes to expand the ‘Magnetic Resonance (MR) Conditional’ labeling to include prone positioning for the Eterna and Proclaim SCS Systems, as well as update the radiofrequency (RF) heating conditions and lead tip implant location for supine positioning for the Proclaim SCS System to ensure consistency in the labeling between the Eterna and Proclaim SCS Systems

Source documents

Other decisions for ABBOTT MEDICAL

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.